VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S.

Antibodies are the body's superheroes, recognizing and eliminating disease-causing substances. By combining parts from antibodies, researchers at Lund University have designed a hybrid antibody that ...

Antibody therapeutics are a rapidly growing class of drugs used to treat infections as well as a range of diseases. Among them are cancer and autoimmunity particularly important, and the use of ...

The blood-brain barrier blocks the entry of antibodies into the brain. This limits the potential use of antibody therapeutics to treat brain diseases, such as brain tumors. Elsewhere in the body, more ...

GlobalData analyst Vasilis Roumpelakis notes that bispecifics could hold strong potential in the future, but manufacturing ...

SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, based on its proprietary ...

NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 ...

LOVELAND, Colo.--(BUSINESS WIRE)--Antech™, a global veterinary diagnostics, technology and imaging company, today announced the launch of two new vector-borne disease diagnostics in their expanding ...